888 related articles for article (PubMed ID: 14529770)
1. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy.
Hagan MP; Winter KA; Kaufman DS; Wajsman Z; Zietman AL; Heney NM; Toonkel LM; Jones CU; Roberts JD; Shipley WU
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):665-72. PubMed ID: 14529770
[TBL] [Abstract][Full Text] [Related]
2. Invasive bladder carcinoma: preliminary report of selective bladder conservation by transurethral surgery, upfront MCV (methotrexate, cisplatin, and vinblastine) chemotherapy and pelvic irradiation plus cisplatin.
Marks LB; Kaufman SD; Prout GR; Heney NM; Griffin PP; Shipley WU
Int J Radiat Oncol Biol Phys; 1988 Oct; 15(4):877-83. PubMed ID: 3182328
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
[TBL] [Abstract][Full Text] [Related]
4. A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer.
Zietman AL; Shipley WU; Kaufman DS; Zehr EM; Heney NM; Althausen AF; McGovern FJ
J Urol; 1998 Nov; 160(5):1673-7. PubMed ID: 9783929
[TBL] [Abstract][Full Text] [Related]
5. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial.
Mitin T; Hunt D; Shipley WU; Kaufman DS; Uzzo R; Wu CL; Buyyounouski MK; Sandler H; Zietman AL
Lancet Oncol; 2013 Aug; 14(9):863-72. PubMed ID: 23823157
[TBL] [Abstract][Full Text] [Related]
6. [Conservative treatment with chemotherapy and radiotherapy in bladder cancer invading the muscle: preliminary results of a prospective study].
Zapatero A; Pinar B; Arellano R; López M; Marín A; Jiménez U; Pérez Torrubia A
Arch Esp Urol; 1997 Jun; 50(5):448-54; discussion 454-6. PubMed ID: 9382586
[TBL] [Abstract][Full Text] [Related]
7. The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response.
Kaufman DS; Winter KA; Shipley WU; Heney NM; Chetner MP; Souhami L; Zlotecki RA; Sause WT; True LD
Oncologist; 2000; 5(6):471-6. PubMed ID: 11110598
[TBL] [Abstract][Full Text] [Related]
8. Initial results of retrospective study: preoperative transurethral excision plus chemotherapy and radiation therapy and trial of bladder preservation.
Gamal El-Deen HS
J Egypt Natl Canc Inst; 2007 Jun; 19(2):133-46. PubMed ID: 19034344
[TBL] [Abstract][Full Text] [Related]
9. Bladder preservation by combined modality therapy for invasive bladder cancer.
Kachnic LA; Kaufman DS; Heney NM; Althausen AF; Griffin PP; Zietman AL; Shipley WU
J Clin Oncol; 1997 Mar; 15(3):1022-9. PubMed ID: 9060542
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802.
Tester W; Caplan R; Heaney J; Venner P; Whittington R; Byhardt R; True L; Shipley W
J Clin Oncol; 1996 Jan; 14(1):119-26. PubMed ID: 8558186
[TBL] [Abstract][Full Text] [Related]
11. Bladder preservation multimodality therapy as an alternative to radical cystectomy for treatment of muscle invasive bladder cancer.
Maarouf AM; Khalil S; Salem EA; ElAdl M; Nawar N; Zaiton F
BJU Int; 2011 May; 107(10):1605-10. PubMed ID: 20825396
[TBL] [Abstract][Full Text] [Related]
12. Combination transurethral resection, systemic chemotherapy, and pelvic radiotherapy for invasive (T2-T4) bladder cancer unsuitable for cystectomy: a phase I/II Southwestern Oncology Group study.
Einstein AB; Wolf M; Halliday KR; Miller GJ; Hafermann M; Lowe BA; Meyers FJ; Leimert JT; Crawford ED
Urology; 1996 May; 47(5):652-7. PubMed ID: 8650861
[TBL] [Abstract][Full Text] [Related]
13. Conservative treatment with transurethral resection, neoadjuvant chemotherapy followed by radiochemotherapy in stage T2-3 transitional bladder cancer.
Cobo M; Delgado R; Gil S; Herruzo I; Baena V; Carabante F; Moreno P; Ruiz JL; Bretón JJ; Del Rosal JM; Fuentes C; Moreno P; García E; Villar E; Contreras J; Alés I; Benavides M
Clin Transl Oncol; 2006 Dec; 8(12):903-11. PubMed ID: 17169764
[TBL] [Abstract][Full Text] [Related]
14. Combined chemotherapy and radiation with selective organ preservation for muscle-invasive bladder carcinoma. A single-institution phase II study.
Fellin G; Graffer U; Bolner A; Ambrosini G; Caffo O; Luciani L
Br J Urol; 1997 Jul; 80(1):44-9. PubMed ID: 9240179
[TBL] [Abstract][Full Text] [Related]
15. Concurrent chemoradiotherapy for clinical stage T2 bladder cancer: report of a single institution.
Peyromaure M; Slama J; Beuzeboc P; Ponvert D; Debré B; Zerbib M
Urology; 2004 Jan; 63(1):73-7. PubMed ID: 14751352
[TBL] [Abstract][Full Text] [Related]
16. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03.
Shipley WU; Winter KA; Kaufman DS; Lee WR; Heney NM; Tester WR; Donnelly BJ; Venner PM; Perez CA; Murray KJ; Doggett RS; True LD
J Clin Oncol; 1998 Nov; 16(11):3576-83. PubMed ID: 9817278
[TBL] [Abstract][Full Text] [Related]
17. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy.
Kaufman DS; Winter KA; Shipley WU; Heney NM; Wallace HJ; Toonkel LM; Zietman AL; Tanguay S; Sandler HM
Urology; 2009 Apr; 73(4):833-7. PubMed ID: 19100600
[TBL] [Abstract][Full Text] [Related]
18. Preliminary results in invasive bladder cancer with transurethral resection, neoadjuvant chemotherapy and combined pelvic irradiation plus cisplatin chemotherapy.
Prout GR; Shipley WU; Kaufman DS; Heney NM; Griffin PP; Althausen AF; Bassil B; Nocks BN; Parkhurst EC; Young HH
J Urol; 1990 Nov; 144(5):1128-34; discussion 1134-6. PubMed ID: 2122007
[TBL] [Abstract][Full Text] [Related]
19. Concurrent cisplatin, 5-fluorouracil, leucovorin, and radiotherapy for invasive bladder cancer.
Chen WC; Liaw CC; Chuang CK; Chen MF; Chen CS; Lin PY; Chang PL; Chu SH; Wu CT; Hong JH
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):726-33. PubMed ID: 12788178
[TBL] [Abstract][Full Text] [Related]
20. A pilot study of chemotherapy alternating with twice-a-day accelerated radiation therapy as an alternative to cystectomy in muscle infiltrating (stages T2 and T3) cancer of the bladder: preliminary results.
Vikram B; Malamud S; Silverman P; Hecht H; Grabstald H
J Urol; 1994 Mar; 151(3):602-4. PubMed ID: 8308967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
